Astrazeneca PLC (AZN) closed at $184.45 on November 13, 2026, unchanged from the previous close, on volume of 1,791,371 shares (30-day average 3,006,434).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 15, 2026 | Calendar Call Ladder | 16-Oct-26170 C|15-Jan-27180 : 210 C | 47,016 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Business Wire (Fri, 13-Nov 6:39 PM ET)
AstraZeneca gains additional bladder cancer indication for Imfinzi
Seeking Alpha News (Fri, 13-Nov 4:23 PM ET)
AstraZeneca eliminates 600 respiratory and immunology sales reps: Bloomberg
Seeking Alpha News (Fri, 13-Nov 2:51 PM ET)
AstraZeneca Updates Benralizumab Asthma Study: What Investors Should Know
TipRanks (Fri, 13-Nov 11:30 AM ET)
AZN’s Tezepelumab Real-World Study Reaches Completion in Russia
TipRanks (Thu, 12-Nov 11:30 AM ET)
TipRanks (Wed, 11-Nov 8:50 AM ET)
Business Wire (Tue, 10-Nov 3:20 PM ET)
AstraZeneca acquires preclinical biotech Omniose
Seeking Alpha News (Tue, 10-Nov 11:21 AM ET)
Deutsche Bank Remains a Hold on AstraZeneca (AZN)
TipRanks (Mon, 9-Nov 8:08 AM ET)
Gabelli Releases Agenda for 8th Annual Healthcare Symposium
Globe Newswire (Mon, 9-Nov 8:00 AM ET)
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Astrazeneca PLC trades on the NYSE stock market under the symbol AZN.
As of November 13, 2026, AZN stock price climbed to $184.45 with 1,791,371 million shares trading.
AZN has a beta of -0.44, meaning it tends to be less sensitive to market movements. AZN has a correlation of 0.01 to the broad based SPY ETF.
AZN has a market cap of $285.95 billion. This is considered a Mega Cap stock.
Last quarter Astrazeneca PLC reported $16 billion in Revenue and $2.79 earnings per share. This beat revenue expectation by $195 million and exceeded earnings estimates by $1.35.
In the last 3 years, AZN traded as high as $212.71 and as low as $60.47.
The top ETF exchange traded funds that AZN belongs to (by Net Assets): PVAL, AVDE, DIHP, DFIC, PPH.
AZN has outperformed the market in the last year with a return of +117.9%, while the SPY ETF gained +13.4%. In the last 3 month period, AZN beat the market returning +17.3%, while SPY returned -2.8%. However, in the most recent 2 weeks AZN has underperformed the stock market by returning -1.2%, while SPY returned -0.2%.
AZN support price is $181.05 and resistance is $187.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AZN shares will trade within this expected range on the day.
